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Abstract
Background: FGFR1 amplification, but not overexpression, has been related to adverse prognosis in hormone-
positive breast cancer (HRPBC). Whether FGFR1 overexpression and amplification are correlated, what is their
distribution among luminal A or B HRPBC, and if there is a potential different prognostic role for amplification and
overexpression are currently unknown features. The role of FGFR1 inhibitors in HRPBC is also unclear.
Methods: FGFR1 amplification (FISH) and overexpression (RNAscope) were investigated in a N = 251 HRPBC patients
cohort and the METABRIC cohort; effects on survival and FISH-RNAscope concordance were determined. We
generated hormonal deprivation resistant (LTED-R) and FGFR1-overexpressing cell line variants of the ER+ MCF7
and T47-D and the ER+, FGFR1-amplified HCC1428 cell lines. The role of ER, CDK4/6, and/or FGFR1 blockade alone
or in combinations in Rb phosphorylation, cell cycle, and survival were studied.
Results: FGFR1 overexpression and amplification was non-concordant in > 20% of the patients, but both were
associated to a similar relapse risk (~ 2.5-fold; P < 0.05). FGFR1 amplification or overexpression occurred regardless of
the luminal subtype, but the incidence was higher in luminal B (16.3%) than A (6.6%) tumors; P < 0.05. The Kappa
index for overexpression and amplification was 0.69 (P < 0.001). Twenty-four per cent of the patients showed either
amplification and/or overexpression of FGFR1, what was associated to a hazard ratio for relapse of 2.6 (95% CI 1.44–
4.62, P < 0.001). In vitro, hormonal deprivation led to FGFR1 overexpression. Primary FGFR1 amplification, engineered
mRNA overexpression, or LTED-R-acquired FGFR1 overexpression led to resistance against hormonotherapy alone or
in combination with the CDK4/6 inhibitor palbociclib. Blocking FGFR1 with the kinase-inhibitor rogaratinib led to
suppression of Rb phosphorylation, abrogation of the cell cycle, and resistance-reversion in all FGFR1 models.
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Conclusions: FGFR1 amplification and overexpression are associated to similar adverse prognosis in hormone-
positive breast cancer. Capturing all the patients with adverse prognosis-linked FGFR1 aberrations requires assessing
both features. Hormonal deprivation leads to FGFR1 overexpression, and FGFR1 overexpression and/or amplification
are associated with resistance to hormonal monotherapy or in combination with palbociclib. Both resistances are
reverted with triple ER, CDK4/6, and FGFR1 blockade.
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Introduction
Hormone receptor-positive (HR+) breast cancer ac-
counts for up to 2/3 of the new breast cancer cases. In
the long term, more than 20% of HR+ breast cancer pa-
tients ultimately die from their disease after developing
distant relapse [1, 2]. From the molecular landscape
point of view, HR+ breast cancer is a highly heteroge-
neous disease [3–5], although in the clinical setting, it is
commonly classified as luminal A or luminal B (herein
Lum-A and Lum-B) based on either the Ki67 replicative
fraction [6, 7] or gene-based recurrence scores [7–13].
The relapse pattern of Lum-A and Lum-B cancers (usu-
ally several years after the completion of hormonal ther-
apy in the former [1, 2, 14], and more commonly during
or shortly after adjuvant hormonal treatment in the latter
[14]) suggests that resistance to hormonal therapy plays a
key role in the relapse. Hormonal resistance is a complex
phenotype that can be caused by different molecular alter-
ations, reviewed elsewhere [15, 16]. One of these factors is
the amplification of fibroblast growth factor receptor 1
(FGFR1) [17]. Retrospective studies suggest that 10–15%
of primary HR+ breast cancer patients harbor this amplifi-
cation [3, 17, 18]. FGFR1 amplification has been linked to
ligand-dependent and ligand-independent increases in
MAPK and Pi3K activation and resistance to hormonal in-
hibitors [17, 19–21]. Selective FGFR inhibitors (1–4) have
shown activity in tumors with FGFRs mutations, amplifi-
cations, or fusions [19, 22–25]. The role of FGFR inhibi-
tors in breast cancer, however, is yet unclear [26–29].
Preclinical and clinical data suggest limited single-agent
efficacy [24, 29, 30]. There is considerable preclinical evi-
dence regarding the additive effects in combination with
hormonal blockade [17, 20], but this evidence has not
translated into strong clinical activity [26, 27]. With the
current number of available options for advanced HR+
breast cancer [31–38], the development of FGFR inhibi-
tors will be challenging unless a biomarker that narrows
down the population that will benefit from FGFR1 block-
ade and a specific therapeutic niche are determined.
The correlation between amplification and overexpression
and the prognostic/predictive role of overexpression of
FGFR1 are less clear than those for that human epidermal
growth factor 2 (HER2), which is amplified or overexpressed
in a similar number of breast cancer cases [39, 40].
Anecdotal studies have reported on FGFR1 overexpression
in breast cancer cohorts [41–43], but a standardized test for
diagnosing overexpression has been lacking so far. In
addition, its prognostic role is currently unknown. Whether
amplification and/or overexpression have a distinct distribu-
tion among Lum-A and Lum-B patients is also unknown.
In this work, we studied in the incidence and prognostic
role of amplification and overexpression of FGFR1 in a co-
hort of Lum-A and Lum-B HR+ breast cancer patients.
FGFR1 mRNA overexpression was determined with a re-
cently developed reproducible assay termed RNAscope
[44, 45]. We show that up to 25% of HR+ breast cancer
cases harbor amplification and/or overexpression of
FGFR1. Both features imply a high risk of relapse. In vitro,
we found that prolonged hormonal deprivation leads to
FGFR1 overexpression and that FGFR1-overexpressing
models are insensitive to the combination of fulvestrant
plus palbociclib, maintaining a resilient retinoblastoma
protein (Rb) phosphorylation and active cell cycle despite
the double blockade. FGFR1-amplified or -overexpressing
models treated with hormones plus palbociclib were fully
eradicated only when rogaratinib (a pan-FGFR1-4 inhibi-
tor that displays activity in different tumors with diverse
molecular alterations in FGFR1-4) [46, 47] was added.
Patients and methods
Patients
Female patients with a diagnosis of primary, non-
metastatic breast cancer with expression of estrogen and/
or progesterone receptor > 1% and lack of HER2 amplifi-
cation diagnosed between January 2001 and December
2002 at Hospital 12 de Octubre were eligible for this study
(H12O cohort). The data cutoff for the follow-up of pa-
tients was 10 years later (2012), although some patients
discontinued clinical follow-up earlier and thus were lost-
to-follow-up. The study protocol was approved by the In-
stitutional Review Board of Hospital 12 de Octubre (Ref:
11/137). Access to the METABRIC dataset was granted by
Drs. Rueda and Caldas.
Fluorescence in situ hybridization (FISH) determination
and RNAscope
FISH chromosome enumeration probes specifically recog-
nizing FGFR1 were purchased from ZytoVision (ZytoLight
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SPEC FGFR1/CEN8 Dual Color Probe). FISH analyses
were performed according to the manufacturers’ instruc-
tions. FISH images were captured using a CCD camera
(Photometrics SenSys camera) connected to a PC running
the Zytovision image analysis system (Applied Imaging
Ltd., UK). Signals were counted in at least 200 cells using
the appropriate filters. Results were expressed as the ratio
of gene signal to centromere (control) using the following
ratios: FISH ratio lower than 1.8 indicates no gene amplifi-
cation (negative), a ratio higher than 2.2 as gene amplifica-
tion (positive), and a ratio between 1.8 and 2.2 as
equivocal cases. The gene/chromosome copy number al-
terations were also recorded in the cells as four gene and
control signals as moderate polysomy and more than four
gene and control signals as high polysomy.
Regarding RNAscope, tissue samples were fixed in
10% neutral buffered formalin (4% formaldehyde in solu-
tion), paraffin-embedded and cut at 4 μm, mounted in
superfrost®plus slides, and dried overnight. RNAscope
staining method was performed in an automated immu-
nostaining platform (Ventana Discovery ULTRA,
Roche). Antigen retrieval was first performed with the
appropriate buffer and protease (RNAscope VS Univer-
sal Sample Prep ReagentV2, 323740, ACD), and en-
dogenous peroxidase was blocked (peroxide hydrogen at
3%). Then, slides were incubated with the human FGFR1
probe, transcript variant 1, mRNA (ACD, 310079). Slides
were then incubated with the corresponding Probe
Amplification kit (RNAscope VS Universal HRP Detec-
tion Reagent, 323210, ACD), conjugated with horserad-
ish peroxidase and reaction was developed using 3,
-diaminobenzidinetetrahydrochloride (DAB Detection
Kit, 760-224, Ventana, Roche); nuclei were counter-
stained with Hematoxylin II and slides were mounted.
Positive control sections were included for each staining
run using Positive Control Probe_Hs-PPIB (313,909,
ACD). Samples were acquired and digitalized using the
AxioScan.Z1 system (Zeiss). Digitalized images were an-
alyzed with the ZEN 2.3 lite software (Zeiss), and tu-
moral areas were categorized in the different scores:
score 0 (no staining or < 1 dot/10 cells), score 1 (1–3
dots/cell), score 2 (4–9 dots/cell and none or very few
are in clusters), score 3 (10–15 dots/cell and < 10% dots
are in clusters), and score 4 (> 15 dots/cell and > 10%
dots are in clusters). Scores of 3 and 4 were considered
RNAscope-positive.
In vitro experiments
MCF7, T47-D, and HCC1428 cells were acquired from
the American Type Culture Collection (ATCC). Cells
were maintained following the ATCC recommendations
and routinely tested for mycoplasma using the Mycoa-
lertTM Mycoplasma Detection Kit (Lonza). Cell lines
were authenticated every 6 months using short-tandem
repeat profiling. Cell line clones resistant to estrogen
deprivation were generated following the method de-
scribed by Martin et al [48, 49]. Briefly, the method con-
sisted of weekly passage and culture of cells in medium
containing 10% dextran charcoal-stripped (DCC) fetal
bovine serum (FBS) (Sigma) instead of full FBS, which
removes steroids. The medium was changed every 2–3
days for 2 years until acquisition of the LTED-R
phenotype.
A retroviral vector for human FGFR1 overexpression
(pWZL_Neo_Myr_Flag_FGFR1) was purchased from
Addgene (Cat#20486). To generate stably transduced
human cells (MCF7 and T47-D), 4 μg of FGFR1-
encoding plasmid was co-transfected with 3 μg of pCL-
Ampho retrovirus packaging vector (Imgenex, Cat#10046P)
into HEK 293 T cell using Lipofectamine 2000 (Thermo
Fisher). HEK 293T medium was changed 24 h post-
transfection. Virus-containing supernatants were harvested
48 h post-transfection, passed through a 0.45-mμ filter, di-
luted 1:4, and applied to target cells with 8 μg/mL poly-
brene (Sigma Aldrich). Transduced cells were selected in
750 μg/mL neomycin.
Colony-formation assays were conducted as follows:
breast cancer cell lines were seeded at densities of 1500
(MCF7, MCF7-FGFR1, MCF7-LTED-R, T47-D, T47-D-
FGFR1, and T47-D-LTED-R) and 4000 (HCC1428 and
HCC1428-LTED-R) cells per well in 12-well plates. After
overnight incubation, medium was replaced with fresh
medium with either vehicle (control) or drugs. Rogarati-
nib and palbociclib were obtained from Bayer Inc. and
Pfizer Inc. respectively, through material transfer agree-
ments. Fulvestrant was purchased from MedChem Ex-
press. Media and drugs were refreshed every 3–4 days.
After 10 days of culture, cells were fixed and stained
with 0.1% (w/v) crystal violet in 10% (v/v) ethanol. All
experiments were performed at least in triplicate. The
well area covered by colonies (colony area intensity) was
quantified automatically from flatbed scanner-acquired
images of colony assays conducted in multi-well plates
using the ImageJ software [50].
To determine the inhibitory concentration of 50%
(IC50) of fulvestrant and palbociclib in MCF7, T-47D,
and HCC1428 cell lines, clonogenic survival assays were
performed. Cells were exposed to a concentration range
of fulvestrant and palbociclib. The IC50 values were de-
rived by a sigmoidal dose-response (variable slope) curve
using GraphPad Prism software version 5.04. Values
shown in Supplemental Table 2 represent the mean of
three independent experiments.
Regarding cell-cycle assays, cells were pre-treated with
drugs or vehicle for 48 h and then 10 μM BrdU was
added to the medium for 30min before harvesting. Fixed
cells were treated with 2M HCl for 20 min, and BrdU
was immunolabeled with FITC-conjugated anti-BrdU
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(Cat. 556028, BD Pharmigen™). For DNA-content ana-
lysis, cells were fixed in 70% ethanol, washed in PBS,
and stained with 50 μg/ml propidium iodide (Sigma) in
the presence of 10 μg/ml RNase A (Qiagen). Flow cy-
tometry data were acquired in a FACSCanto cytometer
(BD Biosciences) and analyzed with FlowJo software
(Tree Star Inc.).
The following primary antibodies were used for immuno-
blots: phospho-Rb (Ser780), Rb (clone D20), FGFR-1 (clone
D8E4), pFRS2 (Tyr196), pFRS2 (Tyr436) (all from Cell
Signaling Technology), CCND1 (clone A12, Santa Cruz),
FRS2 (Proteintech), and pFGFR1 (Tyr653/654) (Invitrogen).
Vinculin and β-Actin (clone AC-15) (Sigma) were used as a
loading control. Membranes were incubated with appropri-
ate peroxidase-conjugate secondary antibodies (Sigma, St
Louis, MO, USA). Bands were visualized by the enhanced
chemiluminescence (ECL) method (Lumi-LightPlus de-
tection kit; Roche). FGFR1, 2, 3, and 4 expression was
performed using TaqMan technology using TaqMan®
Fast Advanced Master Mix (Applied Biosystems) in a
QuantStudio™ 6 Flex Real-Time PCR system (Applied
Biosystems). The probes from Applied Biosystems were
used for FAM/MGB-NFQ FGFR1 (Hs00241111_m1),
FAM/MGB-NFQ FGFR2 (Hs01552918_m1), FAM/
MGB-NFQ FGFR3 (Hs00179829_m1), FAM/MGB-
NFQ FGFR4 (Hs01106910_g1), and FAM/MGB-NFQ
TFRC (Hs00951083_m1), as housekeeping genes.
Statistics
Survival functions were computed using the Kaplan-
Meier estimator. Differences in survival between groups
were assessed using the Log-Rank test. The hazard ratio
for relapse risk for the different tested subgroups deter-
mined by the luminal A or B status and/or FGFR1-
overexpression/amplification were obtained fitting a
Cox’s proportional hazards model. The concordance
analysis between FISH and RNAscope was performed
with the Kappa index. The correlation analysis to evalu-
ate the association between FGFR1 overexpression and
FGFR1 gene copy number was performed with the Pear-
son test. The number of amplified cases among luminal
A and B cases were compared with Fisher’s exact test.
All tests were two-tailed and were performed with the
SPSS Statistics V.19.0 software.
Results
FGFR1-amplified and/or FGFR1 mRNA-overexpressing
hormone-positive cases have an adverse clinical course
We first studied the role of FGFR1 amplification (ratio
FGFR1/centromere > 2.2) in a retrospective series of
N = 251 patients (H12O cohort). The clinical and demo-
graphic characteristics of this cohort are listed in Table 1.
Patients with FGFR1 amplification (11.8%; N = 23/195;
fluorescence in situ (FISH) did not yield a valid result in
56 patients) displayed a significantly worse prognosis.
Median relapse-free survival time was not reached in
FGFR1-non-amplified patients (average 11.2 years) com-
pared to a median relapse-free survival time of 9.5 years
(average 9.3 years) in patients with FGFR1 amplification
(Log-Rank P = 0.035; Fig. 1a). Since it has been proposed
that FGFR1 might confer an adverse prognosis only in
cases of “high amplification” [29], we also tested the
prognostic effect in patients harboring a ratio FGFR/
centromere of > 4 and > 6 (Supplemental Figure 1); the
number of amplified patients following such definitions
were lower and thus the significance was preserved only
for the first case.
According to Ki67 staining, the H12O series was com-
posed by N = 124 (49.4%) Lum-A and N = 127 (50.6%)
Lum-B cases; FGFR-1 was amplified in a significantly
higher percentage of Lum-B (16.3%; N = 17/103; FISH
not valid in 24 patients) than Lum-A (6.6%; N = 6/92;
FISH not valid in 32 patients) patients (P = 0.044). The
FGFR1 to CEN8 FISH ratio, Ki67 value, luminal status,
and survival information are listed in Supplemental
Table 1. Whereas the hazard ratio for relapse conferred
by FGFR1 amplification was statistically significant
(HR = 1.96; 95% CI 1.031–3.72; P = 0.038), the signifi-
cance was not preserved when the cohort was split by
the luminal subtype. Median relapse-free survival times
were in Lum-A/FGFR1-non-amplified, Lum-A/FGFR1-
amplified, Lum-B/FGFR1-non-amplified, and Lum-B/
FGFR1-amplified, respectively: not reached (average
12.5 years), 9.5 years (average 10.8 years), not reached
(average 9.4 years), and not reached (average 7.3 years).
The overall Log-Rank P value for the relapse-free time
comparison among the 4 groups was < 0.001; the pair-
wise comparisons were as follows: Lum-A/FGFR1-non-
amplified versus Lum-A/FGFR1-amplified: P = 0.22; haz-
ard ratio for relapse 3.4 (95% CI 1.12–10.57; P = 0.031);
Lum-B/FGFR1-non-amplified versus Lum-B/FGFR1-
amplified: P = 0.62; hazard ratio for relapse: 1.21 (95% CI
0.55–2.64; P = 0.62); the Kaplan-Meier curves are shown
in Fig. 1b).
We then validated externally our findings in the
METABRIC study cohort, constituted by 1992 breast
cancer patients, where the intrinsic subtype was deter-
mined by gene expression. The cohort is described else-
where [3] and was constituted by mostly low-risk
patients. Of them, 998 cases where either estrogen
receptor-positive and/or progesterone receptor-positive,
HER2-negative, and either Lum-A or Lum-B (herein,
METABRIC Lum-A/B). The main clinical and demo-
graphic characteristics of these 998 patients are shown
in Table 1. In general, compared to the H12O cohort,
these cases displayed more benign characteristics such
as older age or more frequent T1/T2 and N0/N1 stages
and Lum-A profile. Seventy-six (7.6%) of METABRIC
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Lum-A/B patients harbored FGFR1 amplification. These
patients had an adverse disease course compared to the
remainder, with a median relapse-free survival of 12.2
years compared to 21.1 years for the patients without
FGFR1 amplification (Log-Rank P = 0.029; Fig. 1c).
Six hundred and thirty-five METABRIC Lum-A/B
were Lum-A (63.6%) whereas 363 (36.4%) were Lum-B.
Akin to the high-risk H12O series, the percentage of
FGFR1 amplifications was higher in Lum-B cases (11.1%
versus 5.5% in Lum-A cases; P = 0.001). The median
relapse-free survival for Lum-A/FGFR1-non-amplified,
Lum-A/FGFR1-amplified, Lum-B/FGFR1-non-amplified,
and Lum-B/FGFR1-amplified subgroups was 22.7, 15.2,
13.6, and 9.8 years, respectively (overall Log-Rank P <
0.001). The pairwise comparisons, however, akin the
H12O series, lost significance when the series was split
by the luminal subtype: regarding Lum-A, the Log-Rank
P value was 0.39, whereas for Lum-B cases, the Log-
Rank P was 0.21; the hazard ratio for relapse were, re-
spectively, 1.27 (95% CI 0.72–2.23) and 1.3 (95% CI
0.85–2.04); Fig. 1d).
We then analyzed FGFR1 RNA expression levels by
RNAscope in the H12O cohort. Out of 165 cases with a
valid result, 28 of them (17%) were RNAscope positive
(score of 3 or 4, herein FGFR1-overexpressed) (Supple-
mental Table 1). The rate of positivity was higher than
the percentage of FGFR1-amplified cases in the H12O
(P = 0.07) and METABRIC Lum-A/B series (P < 0.001).
There were more RNAscope-positive cases among Lum-
B than Lum-A patients (24.4% versus 8.0%; P < 0.001).
(Supplemental Table 1). The concordance between posi-
tivity in FGFR1 by FISH and RNAscope is depicted in
Fig. 1e (it was considered only samples with valuable in-
formation for both techniques). The Kappa index for this
concordance was 0.69 (P < 0.001); examples matching
and non-matching results in FISH and RNAscope are
shown in Fig. 1e. FGFR1 copy number and FGFR1







(N = 998 patients)
Age (median, range) 54.0 (20.2–91.0) 63.9 (26.3–90.4)
Tumor size
T1 126 (50.2%) 440 (44.0%)
T2 96 (38.2%) 519 (52.0%)
T3 23 (9.1%) 36 (3.6%)
T4 6 (2.4%) N/A**
N/A 0 (0%) 5 (0.5%)
Nodal status
N0 108 (43.1%) 540 (54.0%)
N1 85 (33.9%) 313 (31.3%)
N2 38 (15.1%) 105 (10.5%)
N3 20 (7.9%) 40 (4.0%)
Grade
G1 63 (25.1%) 127 (12.7%)
G2 126 (50.2%) 502 (50.3%)
G3 62 (24.7%) 326 (32.6%)
N/A 0 (0%) 44 (4.4%)
Lum-A/B (defined by Ki67% staining)
< 15% (Lum-A) 124 (49.4%) N/A
> 14% (Lum-B) 127 (50.6%)
Lum-A/B (defined by PAM-50)
Lum-A N/A 635 (63.6%)
Lum-B 363 (36.4%)
Adjuvant/neoadjuvant chemotherapy
No 63 (25.1%) 920 (92.2%)
Yes 188 (74.9%) 78 (7.8%)
CMF or capecitabine 38 (15.1%) 14 (1.4%)
Anthracycline based 87 (34.7%) 38 (3.8%)
Taxane based 63 (25.1%) 4 (0.4%)
Other 0 (0%) 22 (2.2%)
Adjuvant hormonal therapy
No 13 (5.2%) 273 (27.4%)
Yes 238 (94.8%) 725 (72.6%)




No 172 (88.2%) 922 (92.4%)





Negative (0, 1+, or
2+)
137 (83%) N/A
Positive (3+ or 4+) 28 (17%) N/A







(N = 998 patients)
Relapse
No 169 (73.3%) 627 (62.8%)
Yes 82 (32.7%) 370 (37.1%)
N/A 0 (0%) 1 (0.1%)
*FGFR amplification was determined in the H12O series by FISH in a tissue
microarray. Conversely, in the METABRIC series, it was determined by CGH
arrays. FISH data were not available in 56 cases; thus, positive/negative cases
are shown in relative percentage to the available cases
**In the METABRIC database, primary tumor is coded by size in millimeters.
What qualifies a primary tumor as T4 is the invasion of the chest wall and/or
skin and/or presence of inflammatory carcinoma, regardless of the tumor size
in millimeters. Thus, the number of T4 tumors in this series is actually
unknown, although the percentage of T4 tumors in routine clinics is
generally low
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Fig. 1 (See legend on next page.)
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RNAscope values also showed a statistically significant posi-
tive correlation (Pearson coefficient: 0.61; P < 0.001). The
effect of FGFR1 overexpression in distant relapse was simi-
lar than that of FGFR1 amplification: the median relapse-
free survival time was not reached for patients without
overexpression (average 10.69 years) compared to 8.6 years
(average 7.7) for the patients with FGFR1 overexpression
(Log-Rank P = 0.021; Fig. 1f). The hazard ratio for relapse
conferred by FGFR1 overexpression was 2.02 (95% CI
1.096–3.73, P = 0.024). The median relapse-free survival
times were in Lum-A/FGFR1 non-overexpressed, Lum-A/
FGFR1-overexpressed, Lum-B/FGFR1 non-overexpressed,
and Lum-B/ FGFR1-overexpressed, respectively: not
reached (average: 11.6 years), not reached (average: 9.7
years), not reached (average: 9.7 years), and 7.3 (average:
6.9 years). The pairwise comparisons (Lum-A/FGFR1 non-
overexpressed versus Lum-A/FGFR1-overexpressed; and
Lum-B/FGFR1 non-overexpressed versus Lum-B/ FGFR1-
overexpressed), however, were not significant: P = 0.56 and
P = 0.143, respectively.
Finally, if we consider together either amplification
and/or overexpression of FGFR1, patients that harbored
any of the two alterations (24.5% of the patients, N = 37/
151) displayed a significantly worse prognosis compared
to patients that did not have any (Fig. 1h; median relapse
free survival of 8.6 years (average 8.8) versus not reached
(average 11.2); Log-Rank P < 0.001; the hazard ratio for
relapse was 2.6 (95% CI 1.44–4.62; P < 0.001)).
Prolonged hormonal deprivation leads to increased
FGFR1 transcriptional levels and cross-resistance with
fulvestrant
The mainstay of treatment for Lum-A/B tumors in the
adjuvant setting is hormonal blockade. The majority of
Lum-A/B patients receive 5–10 years of hormonal block-
ade in the adjuvant setting. Aromatase inhibitors are the
most frequently prescribed agents, and they reduce the
available estrogens in the organism to non-detectable
levels. FGFR1 signaling has been implicated in resistance
to hormonal inhibition [3, 17–21]; in addition, hormonal
deprivation has been related to FGFR1 overexpression
[20]. In order to mimic this scenario in vitro, and to as-
certain its functional role, we exposed 2 FGFR1-non-
amplified (MCF7, T-47D) and 1 FGFR1-amplified
(HCC1428) breast cancer cell line to prolonged
hormonal deprivation (> 2 years) (Fig. 2a). The three cell
lines acquired the long-term estrogen-deprivation resist-
ant phenotype (LTED-R). MCF7 and T-47D parental cell
lines had a > 90% decrease in relative plating efficiency
(RPE) whereas HCC1428 (FGFR1-amplified) had around
a 40% decrease in RPE in 10-days colony assay experi-
ments in estrogen-free DCC media. Conversely, MCF7-
LTED-R, T-47D-LTED-R, and HCC1428-LTED-R vari-
ants showed very similar plating efficiency rates in
estrogen-free and -full media (Fig. 2b). Interestingly, the
LTED-R phenotype was cross-resistant to fulvestrant (a
selective estrogen receptor degrader which is a com-
monly used agent in combination with CDK4/6 inhibi-
tors upon metastatic relapse [31–34]), as shown by the
limited effects in plating efficiency observed for the three
LTED-R variants compared to the parental cell lines
(Fig. 2c). As it can be observed, for FGFR1-amplified cell
line HCC1428, a 10-fold higher fulvestrant concentra-
tion than that required for MCF7 and T-47D cell lines
was required to have a suppressive effect on parental cell
line (Fig. 2c).
Prolonged hormonal deprivation has been related with
FGFR1 overexpression [20], but whether this reflects the
selection of previously existing clones or is the result of
a new genomic event is currently unknown. Interest-
ingly, both MCF7-LTED and T-47D-LTED variants
showed a polysomic (but not amplified) FGFR1 locus in
FISH, increased FGFR1 mRNA levels by RT-PCR, posi-
tive RNAscope staining, and increased FGFR1 protein
levels compared to the parental cell lines (Fig. 2d). These
data suggest that cell line subclones with increased
FGFR1 genetic and transcriptomic levels were positively
selected during the LTED phenotype acquisition experi-
ment. Whether these clones were previously present
(“persistence”) and expanded through the 2-year selec-
tion process, or appeared de novo by mutational pro-
cesses, it is difficult to ascertain with the current data.
However, the limited cellular replication during the
acquisition of the LTED-R phenotype (Supplemental
Figure 2A) and the presence of a minor number of poly-
somic cells in the parental cell lines (Supplemental Fig-
ure 2B) may suggest that the persistence and expansion
of resistant clones explains the phenotype.
Finally, we engineered the non-FGFR1-amplified cell
lines T-47D and MCF7 to overexpress FGFR1 (without
(See figure on previous page.)
Fig. 1 Concordance between FGFR1 amplification and overexpression and prognostic impact among hormone-positive breast cancer patients.
Kaplan-Meier curves representing the impact of FGFR1-amplficiation disease relapse risk in the general HR+ breast cancer cohort (a) or split
according to the Lum-A or Lum-B subtypes (b) in the discovery set (H12O series) or in the METABRIC Lum-A/B cohort (c) and (d). e Left panel:
concordance between the result of FGFR1 FISH and RNAscope tests. Right panel: examples of concordant results (positive or negative in both
tests) or non-concordant results (positive/negative or vice versa) in different cases of the H12O series. f, g Same as a and b according to
RNAscope positivity. h Kaplan-Meier curve for distant relapse of patients with FGFR1 amplification and/or FGFR1 mRNA overexpression compared
to non-amplified, non-overexpressed cases. Patients at risk are stated under each Kaplan-Meier curve. Vertical ticks represent censoring events
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amplification). The comparative FISH and RNAscope of
FGFR1 among the two FGFR1-low cell lines (T-47D,
MCF7), their two FGFR1-overexpressing variants (T-
47D-FGFR1 and MCF7-FGFR1; unchanged FISH but in-
creased RNAscope versus the parental), and the FGFR1-
amplified HCC1428 cell line were showed in Fig. 2e and
Supplemental figure 2C. Although engineered FGFR1-
overexpression did not seem to confer primary resist-
ance to estrogen deprivation in MCF7 and T-47D cell
lines (Fig. 2f, left panel), it was clearly related to primary
resistance to fulvestrant (Fig. 2f, right panel; in both
panels the primary FGFR1-amplified HCC1428 is shown
for control purposes). The IC50 for fulvestrant on each
cell line is shown in Supplemental Table 2. Taken to-
gether, these data suggest that the increase of FGFR1
mRNA levels, regardless of the amplification status, is
associated with hormonal resistance. Prolonged estrogen
deprivation leading to increased FGFR1, or primarily
amplified FGFR1, seems to be related to DCC and ful-
vestrant resistance. The fact that engineered FGFR1
overexpression led to resistance to fulvestrant but not to
DCC suggests that during the acquisition of the LTED-R
phenotype, other events may mediate in the process.
Since fulvestrant is commonly prescribed in combination
with a cell cycle inhibitor upon progression to aromatase
inhibitors [33, 34] (i.e., the scenario mirrored by LTED-
R variants), we next explored the sensitivity of these var-
iants to CDK4/6 inhibition and evaluated the blockade
of FGFR1 as a potential way to sensitize them to fulves-
trant plus palbociclib.
Hormone-resistant, FGFR1-amplified, or overexpressed
cell lines are resistant to the double but sensitive to the
triple blockade
Currently, the standard-of-care for metastatic HR+
breast cancer is the combination of either an aromatase
inhibitor or fulvestrant with a CDK4/6 inhibitor, both in
the first and second line [31–36]. Thus, we tested the
sensitivity to hormonal deprivation (DCC) or fulvestrant
plus palbociclib of the primary FGFR1-amplified cell
line, the engineered FGFR1-overexpressing cell lines,
and the LTEDR variants with high FGFR1 mRNA levels.
Compared to the parental cells, FGFR1-overexpressing
engineered and to a greater extent LTED-R variants
were more resistant to DCC, fulvestrant, palbociclib, and
DCC/fulvestrant+palbociclib doublets (Fig. 3a). The pri-
marily amplified cell line HCC1428 and its LTED-R vari-
ant were, as expected, resistant to the combinations as
well (Fig. 3a). Thus, cell lines with increased FGFR1 copy
number or mRNA, primarily or as a result of prolonged
hormonal deprivation, are resistant to the combination
of hormonal deprivation plus palbociclib. The IC50 for
palbociclib in the 7 cell lines is shown in Supplemental
Table 2.
We next tested the effects of FGFR1 inhibition with
the selective pan-FGFR inhibitor rogaratinib [51]. Rogar-
atinib effectively inhibited ERK, FGFR1, and FRS2 phos-
phorylation in response to the FGFR1 ligand bFGF in
FGFR1-high or LTED-R cell lines (Supplemental Figure
3). Despite the evidenced pharmacodynamic effect, how-
ever, rogaratinib did not show efficacy in monotherapy
in any cell line (Supplemental Figure 4). The expression
levels of the other rogaratinib targets, FGFR2, 3, and 4,
are shown in Supplemental Figure 5. These data are in
concordance with published studies that suggest that
FGFR inhibitors in breast cancer would have effect only
in combination with hormonal blockade [17, 20]. How-
ever, the triple combinations of fulvestrant or DCC plus
palbociclib and rogaratinib were the only ones that
achieved 80–100% suppression of RPE in the colony as-
says of all models, including the resistant FGFR1-
amplified and/or FGFR1 mRNA-high LTED-R variants,
FGFR1-overexpressing clones, or native HCC1428 cell
lines (Fig. 3b).
(See figure on previous page.)
Fig. 2 Prolonged hormonal deprivation selects for cells with high FGFR1 mRNA levels which are resistant hormonal deprivation and fulvestrant. a
Cell lines were exposed to estrogen deprivation by culturing and passaging them for > 24 months in regular culture media supplemented with
10% dextran charcoal-stripped (DCC) fetal bovine serum (FBS), what deprives FBS from estrogens. Cells undergo 4 progressive stages from the
basal status (hormone-dependent) until the acquisition of resistance during a ~ 2-year process: quiescent long-term estrogen deprivation (LTED-
Q; most cells have died and a number of cells remain but do not replicate), hypersensitive to estrogens (LTED-H; cells still do not replicate but if
they are exposed to estrogens they replicate fast), estrogen independent (LTED-I; they are able to grow and replicate in absence of hormones
but much slower than the parental), and hormonal-resistant (LTED-R; they behave in absence of hormones akin parental cells in presence of
hormones). b Representative pictures of colony assays and quantification (relative plating efficiency—RPE) of MCF7, T-47D, and HCC1428 and
their LTED-R variants in full or DCC media. For each cell line, RPE is depicted relatively to its own RPE in full media. c Same as in b, comparing
vehicle versus fulvestrant at the depicted concentrations. d FGFR1 genetic (assessed by FISH—upper pictures), transcriptomic (assessed by
RNAscope—lower pictures—and RTPCR—charts) and protein status (determined by western blot) of parental and LTED variants of MCF7 and T-
47D. MCF7-FGFR1 is included in the western blot for control purposes. In FISH pictures: green dots: FGFR1 probe; red dots: chromosome 8
centromere probe. e FGFR1 copy number (FISH, above) and mRNA levels (RNAscope, below) in parental MCF7 and T-47D cell lines or mRNA
levels (RNAscope) for engineered to overexpress FGFR1. The amplified HCC1428 cell lines are included for control purposes. f Colony assays and
RPE of the same cell lines shown in e exposed to estrogen deprivation or fulvestrant (MCF7 cell lines, 0.5 nM; T47-D cell lines, 1.5 nM and
HCC1428 cell line, 20 nM), indicating how FGFR1 mRNA high cell lines are resistant to fulvestrant regardless of amplification. Error bars: standard
error. ***P < 0.001; **P < 0.01; *P < 0.05. Scale bars: FISH, 10 μm; RNAscope, 20 μm
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Epithelial hormone-positive cell lines transduce repli-
cative signals that converge in the phosphorylation and
inactivation of Rb by the CDK4/cyclin-D complex, which
is then targeted for proteasomal degradation [52, 53].
CDK4/6 inhibitors thus block Rb phosphorylation, which
gets stabilized and inhibits the transcription factor E2F,
stopping the entry into S-phase [53, 54]. Alternative
pathways implicated in sustained Rb phosphorylation in
absence of CDK4/6 activity are not well understood;
however, the LTED-R and FGFR1-overexpressed cell
lines displayed a resilient Rb phosphorylation regardless of
hormonal blockade with or without palbociclib (Fig. 4a). It
has to be noted that even in MCF7 and T-47D parental
cells, the treatment with fulvestrant as a single agent does
not suppress pRb levels. In addition, pRb levels are
retained upon palbociclib treatment in LTED-R and
FGFR1-overexpressing cells, despite the greater effect
achieves by palbociclib in parental cells. Although fulves-
trant or palbociclib led to some decrease of phosphoryl-
ation of Rb, the maximum effect was achieved with either
fulvestrant + rogaratinib or fulvestrant + palbociclib +
rogaratinib, which led to complete abrogation in several
models. Similar effects were observed in the HCC1428
model (Fig. 4a). Previous studies have suggested at least a
partial causal role of the FGFR-cyclin D1 axis in resistance
to antiestrogens alone and in combination with CK4/6 in-
hibitors [55]. The reduction in CCND1 protein levels after
triple combination treatment revealed that the effects on
Rb phosphorylation is mediated by inhibition of Cyclin D/
CDK4/6 axis (Fig. 4a).
BrdU incorporation assay performed in the different
models, with or without drugs (monotherapy or combina-
tions), revealed that the suppression of Rb phosphorylation
actually correlated with the effects observed in cell cycle
across the different models, where cells displayed their low-
est S-phase fractions in presence of the triplets (Fig. 4b and
Supplemental Figure 6). Taken together, our data suggest
that HR+ breast cancer cell lines with elevated FGFR1
levels (either because of amplification or increased mRNA
levels) require the combination of ER, CDK4/6 and FGFR1
blockade for maximum cell cycle arrest.
Discussion
In the rapidly evolving field of HR+ breast cancer thera-
peutics, a key objective is how to maintain sensitivity to
hormonal-based therapies for as long as possible, delay-
ing the need for standard cytotoxic chemotherapy. The
recent incorporation of cell cycle inhibitors in the first-
and second-line metastatic setting has revolutionized the
field, doubling the average progression-free survival
times of hormonal treatments alone [31–36]. Other
strategies targeting the Pi3K [37] or the MTOR [38]
pathways have proved successful as well in extending
the time during which patients benefit from hormonal
blockade. However, multiple signaling pathways are in-
volved in the acquisition of hormonal resistance [15].
The contribution to hormonal resistance varies from
one pathway to another, and probably more than one
usually co-exist; in addition, the acquisition of the hor-
monal resistant phenotype is rather a continuum [49]
than a “black or white” situation, and is influenced by
previous length and type of hormonal exposure. The
complex and inter-patient variable genomic landscapes,
together with the effects caused by previous drug expo-
sures, will certainly make the field increasingly challen-
ging in order to individually select the best agent combo
to extend hormonosensitivity.
On top of the mentioned CDK4/6, Pi3K, and MTOR
targets, FGFR1 may be another key signaling axis driving
hormonal resistance. Single-agent FGFR1-inhibitors do
not show sufficiently high activity in advanced HR+
breast cancer to warrant further development [24, 29,
30]. Combinations of a hormonal agent and an FGFR1-
inhibitor show variable activity [26, 27]. Our results ad-
vance in the task of finding a therapeutic scenario and a
patient sub-population where FGFR inhibitors would de-
serve clinical investigation: HR+ breast cancer patients
with amplification and/or overexpression of FGFR1
upon progression to aromatase inhibitors.
The incidence of FGFR1 amplification has been
already described and several studies consistently report
a ~ 10% rate among patients with a primary HRPBC,
which, in turn, is associated with a 2- to 4-fold higher
risk of metastatic relapse [3, 17, 18]. However, the inci-
dence and prognostic role of FGFR1 mRNA overexpres-
sion in breast cancer was previously unknown.
RNAscope is a technique that can determine overexpres-
sion of mRNA in paraffinized samples and has a stan-
dardized quantitation method [44, 45]; FGFR1 has not
been previously studied in breast cancer by this method.
(See figure on previous page.)
Fig. 3 Triple ER, CDK4/6, and FGFR1 blockade reverts resistance in FGFR1-positive models. a Relative plating efficiency (left) and example of
colony assays (right) of parental MCF7, T47-D, and FGFR1-amplified HCC1428 or their FGFR1-overexpressing or LTED-R variants in response to
vehicle, palbociclib (MCF7 cell lines, 50 nM; T47-D and HCC1428 cell lines, 100 nM), fulvestrant (MCF7 cell lines, 0.5 nM; T47-D cell lines, 1.5 nM and
HCC1428 cell lines, 5 nM), DCC, palbociclib plus fulvestrant, or palbociclib plus DCC. b In the same model as in a, the observed resistance against
palbociclib + fulvestrant/DCC was reverted by adding the FGFR1 inhibitor rogaratinib (1 μM), as evidenced by the relative-plating efficiency data.
Statistically significant difference between either vehicle and all combinations or double and triple combinations are shown. Error bars: standard
error. ***P < 0.001; **P < 0.01; *P < 0.05
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Interestingly, in the H12O series, we found that the haz-
ard ratio for metastatic relapse conferred by FGFR1
mRNA overexpression was virtually the same to that
conferred by amplification; however, it affected to a sig-
nificantly greater number of patients (Fig. 1e, f). In
addition, it is worth noting that although most amplified
cases tested positive in RNAscope and vice-versa, there
was a significant number of patients that did not (Fig.
1e), suggesting that not all tumors with FGFR1 amplifi-
cation overexpress FGFR1 and that overexpression can
be achieved without amplification. In order to detect all
patients in which FGFR1 confers an adverse prognosis,
FISH and RNAscope should be performed together: the
Kaplan-Meier curve shown in Fig. 1h shows that patients
that are positive by either technique (or both) have a
hazard ratio of relapse > 2.5. This data can only be
underscored, since as much as 24.5% of the H12O series
tested positive in at least one of the two tests, which rep-
resents a greater percentage of breast cancer patients
than triple-negative or HER2-positive tumors that could
potentially benefit from a targeted agent. Finally, it was
unclear whether FGFR1 amplification or overexpression
was a selective feature of either Lum-A or Lum-B tu-
mors up until now. The characteristics usually associated
with increased FGFR1 signaling (hormone resistance, in-
creased metastatic potential, or increased cell replication
[3, 17–21]) could lead to hypothesize that it might be an
event mostly observed in Lum-B cases. Although the fre-
quency of amplification was higher in Lum-B cases, we
found in the H12O series that a significant percentage of
Lum-A cases (6.6%). The findings were validated in the
METABRIC Lum-A/B cohort, although the percentages
of amplification were lower, in accordance with a gener-
ally better prognosis series (Table 1). In both cases, how-
ever, when the H12O and METABRIC series were split
by the luminal subtypes, FGFR1 amplification or overex-
pression lost their statistical significance. We cannot
think in a plausible biological reason that explains this
phenomenon; rather, it is common to observe that when
the sample sizes are reduced, it affects the statistical
significance, particularly when it is not a highly pene-
trant factor. Similar results—albeit at a considerably
higher frequency than for FGFR1 amplification—were
found for FGFR1-mRNA overexpression (Fig. 1g). Un-
fortunately, since the samples of the METABRIC Lum-
A/B are not currently accessible, RNAscope could not
be validated in this dataset. The same phenomenon (loss
of statistical power) was observed when the H12O was
split by the luminal subtype to study the effects of RNA-
scope positivity in relapse-free survival. The definitive
role of amplification and/or overexpression might re-
quire larger patient series. Similarly, the optimal cutoff
point for defining FGFR amplification (Supplemental
Figure 1) will be better addressed not only with larger
patient series (since the number of patients with ratios
of > 4 and > 6 is progressively smaller) but with the as-
sessment of efficacy of FGFR1 inhibitors in ongoing tri-
als stratified by FGFR1 copy number.
Our findings are potentially useful as well in order to
define a potential therapeutic niche for FGFR1 inhibi-
tors. Currently, most patients debut with metastatic dis-
ease after a number of years exposed to aromatase
inhibitors. Our data show that cell lines chronically ex-
posed to hormonal deprivation become resistant to this
condition (Fig. 2b) and are cross-resistant to fulvestrant
(Fig. 2c). During this process, MCF7 and T-47D upregu-
lated FGFR1 at the transcriptomic and translational level
(Fig. 2d). Both MCF7 and T-47D LTED variants with
high FGFR1 were also resistant to the combination of
hormones (DCC/fulvestrant) plus the CDK4/6 inhibitor
palbociclib. The primarily amplified HCC1428 cell line
was not fully resistant to DCC but it was resistant to ful-
vestrant and fulvestrant + palbociclib (Fig. 3a).
The fact that MCF7 and T-47D cell lines engineered
to overexpress FGFR1 were as well resistant to fulves-
trant and fulvestrant plus palbociclib, and parental
MCF7/T-47D cells were not (Figs. 2c, f and 3a), suggest
that FGFR1 overexpression or amplification is a condi-
tion that can be acquired during hormonal deprivation
and leads to resistance to fulvestrant and fulvestrant plus
(See figure on previous page.)
Fig. 4 Rb phosphorylation and cell cycle suppression with the triple FGFR1, ER, and CDK4/6 blockade. a Western blot showing the
phosphorylation (Ser780) of the Rb protein 48 h after treatments. For each cell line (MCF7 or T47D plus their LTED-R and FGFR1-overexpressing
variants, and the FGFR1-amplified HCC1428 and its LTED-R variant), 7 conditions were tested: vehicle (VEH), fulvestrant (F), rogaratinib (R),
palbociclib (P), fulvestrant plus rogaratinib (F + R), fulvestrant plus palbociclib (F + P), and fulvestrant plus palbociclib plus rogaratinib (F + P + R).
Drug concentrations: MCF7 cell lines: F, 0.5 nM; P, 50 nM; R, 1 μM; T-47D cell lines: F, 1.5 nM; P, 100 nM; R, 1 μM; HCC1428 cell lines: F, 5 nM; P, 100
nM; R, 1 μM. Total Rb and beta-actin are shown for control purposes. It can be appreciated that in the FGFR1-high models (either because of
engineered overexpression, LTED-R phenotypes, or primary amplification), the maximum suppression is achieved in the rogaratinib-containing
combinations. Whereas the doublet (F + R) is highly active in most models, the triplet (F + P + R) is the only one that achieves suppression in all
the models. Conversely, wild-type MCF7 and T-47D do not require rogaratinib for suppression, and actually, the greater effect is achieved by
palbociclib. CCND1 protein levels showing that the effects on pRb are mediated by activation/inhibition of Cyclin D/CDK4/6 axis. b Charts
showing BrdU incorporation (S-phase) of the same models and concentrations as in a, evidencing the translation of the effects over Rb
phosphorylation in the cell cycle. The maximum effects in the FGFR1-high models are achieved by the triplet in all cases. Error bars: standard
error. ***P < 0.001; **P < 0.01; *P < 0.05
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palbociclib. The role of FGFR1 amplification (but not
overexpression) in the acquisition of resistance to riboci-
clib plus hormonal treatment was already known [55];
however, it was unknown that such status could be
achieved just after hormonal exposure. CDK4/6 inhibi-
tors abrogate the entry in the S-phase by suppressing Rb
phosphorylation; akin to Arteaga and Formisano [55],
we found that the FGFR1-overexpressing variants did
not suppress Rb phosphorylation and cell cycle com-
pletely (Fig. 4), unless rogaratinib was added to the drug
combos. We found that the LTED-R variants also
achieved maximum inhibition of Rb phosphorylation
and cell cycle suppression in response to rogaratinib-
containing combos (Fig. 4). Palbociclib plus fulvestrant
was not sufficient to block Rb phosphorylation and abort
the cell cycle, which had strong correlation with the col-
ony assays (Fig. 3a and b) that showed that only the trip-
lets can eradicate the growth of these models.
An additional point that deserves attention is that our
data suggest that the percentage of patients with amplifi-
cation and/or overexpression of FGFR1 in the metastatic
setting might be quite high. Our study found that up to
24.5% of primary HR+ tumors display any of the two al-
terations. Since continuous hormonal deprivation seem
to select for FGFR1 overexpression, it is quite likely that
the percentage is higher in relapsed tumors after adju-
vant aromatase inhibitors. This hypothesis requires a
direct assessment in a collection of metastatic samples
and constitutes a weakness of our study, since we did
not check if the mentioned effect in vitro actually trans-
lates into a large percentage of patients switching from
negative into positive in their metastatic lesions. Meta-
static HR+ sample collections are usually characterized
by several selection biases since usually clinicians sample
metastatic lesions in case patients display atypical fea-
tures. An unbiased sample cohort would be required to
this end. Another weakness is that we did not find a
convincing mechanism that explained why the lack of
estrogens led to a stable overexpression of FGFR1. We
did not find direct transcriptional repression of ER over
the FGFR1 promoter (data not shown); however, the ex-
periments shown in Supplemental Figure 2 suggest a
simple sub-clonal selection of FGFR1-overexpressing
variants. A definitive answer to this matter would re-
quire a single-cell RNAseq approach. Regardless, the ul-
timate mechanism is not relevant at this point since we
just aim to justify a clinical trial with the triple combin-
ation in a specific population selected by the emerging
phenotypic trait of hormonal deprivation: FGFR1 ampli-
fication or overexpression. We eagerly await the efficacy
results of two trials combining erdafitinib, palbociclib,
and fulvestrant (NCT03238196) and rogaratinib, palboci-
clib, and fulvestrant (NCT04483505) in advanced, hor-
monopositive, FGFR1-amplified breast cancer, which
will also help to better understand the correlation be-
tween higher amplification rates of FGFR1 and rogarati-
nib/erdafitinib efficacy.
Conclusions
Taken together, our data suggest that FGFR1 increase at
the genomic or transcriptomic level drives the relapse of
a significant proportion of hormone-positive patients.
The fact that FGFR1 transcriptomic levels increase dur-
ing hormonal deprivation and the increased risk of re-
lapse observed in FGFR1-positive patients suggest that
the proportion of FGFR1-positive patients (by FISH and/
or RNAscope) in the metastatic patients could be con-
siderably high. Since FGFR1 amplification and overex-
pression confer a similar risk, and their concordance is
less than 70%, we believe that FGFR1 should be deter-
mined by combining both FISH and RNAscope in order
to capture all potential candidates for FGFR1 inhibitors.
Concerning the potential therapeutic niche for this drug
class, given the widespread use of aromatase inhibitors
during the adjuvant stage and in first-line metastatic set-
ting, and considering the observed resistance and lack of
complete cell cycle suppression in response to fulves-
trant plus palbociclib, a triplet (fulvestrant plus palboci-
clib plus FGFR1 inhibition) could be studied in the
second line setting. We have recently launched a clinical
trial that will study the tolerability and preliminary effi-
cacy of rogaratinib, fulvestrant, and palbociclib in
FGFR1-positive (by RNAscope and/or FISH) HR+ breast
cancer patients that have progressed to first line CDK4/
6 inhibitor plus aromatase inhibitor in order to address
the role of this driver of HR+ breast cancer
aggressiveness.
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